Toronto Dominion Bank lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 11.4% during the third quarter, HoldingsChannel reports. The firm owned 683,584 shares of the healthcare product maker’s stock after buying an additional 69,747 shares during the quarter. Toronto Dominion Bank’s holdings in Abbott Laboratories were worth $36,474,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sanders Morris Harris LLC lifted its position in Abbott Laboratories by 0.3% in the 2nd quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock valued at $242,000 after acquiring an additional 16 shares in the last quarter. St. Louis Trust Co lifted its position in Abbott Laboratories by 0.4% in the 2nd quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock valued at $238,000 after acquiring an additional 20 shares in the last quarter. Lakeview Capital Partners LLC lifted its position in Abbott Laboratories by 0.6% in the 2nd quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock valued at $277,000 after acquiring an additional 33 shares in the last quarter. Johanson Financial Advisors Inc. lifted its position in Abbott Laboratories by 0.5% in the 2nd quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock valued at $343,000 after acquiring an additional 37 shares in the last quarter. Finally, Country Club Trust Company n.a. lifted its position in Abbott Laboratories by 0.5% in the 2nd quarter. Country Club Trust Company n.a. now owns 7,320 shares of the healthcare product maker’s stock valued at $356,000 after acquiring an additional 38 shares in the last quarter. 71.15% of the stock is currently owned by institutional investors.

In other news, insider Daniel Gesua Sive Salvadori sold 71,157 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $55.00, for a total transaction of $3,913,635.00. Following the transaction, the insider now directly owns 144,955 shares in the company, valued at approximately $7,972,525. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alejandro D. Wellisch sold 2,153 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the transaction, the insider now owns 10,256 shares in the company, valued at $572,900.16. The disclosure for this sale can be found here. Insiders have sold a total of 501,172 shares of company stock worth $27,533,150 over the last 90 days. 0.76% of the stock is owned by company insiders.

Several equities research analysts recently commented on ABT shares. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research report on Friday, September 22nd. Cowen reaffirmed a “buy” rating on shares of Abbott Laboratories in a research report on Sunday, September 24th. Wells Fargo & Co boosted their price objective on shares of Abbott Laboratories from $57.00 to $64.00 and gave the company an “outperform” rating in a research report on Thursday, September 28th. Barclays boosted their price objective on shares of Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, September 28th. Finally, BMO Capital Markets reaffirmed a “hold” rating and issued a $53.00 price objective on shares of Abbott Laboratories in a research report on Monday, October 2nd. Six equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $60.24.

Abbott Laboratories (ABT) opened at $58.83 on Thursday. The firm has a market cap of $102,400.00, a PE ratio of 48.62, a PEG ratio of 1.88 and a beta of 1.55. Abbott Laboratories has a 52 week low of $39.25 and a 52 week high of $59.60. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.01. The company had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. Abbott Laboratories’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.59 EPS. research analysts predict that Abbott Laboratories will post 2.5 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be paid a dividend of $0.28 per share. The ex-dividend date is Thursday, January 11th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 annualized dividend and a dividend yield of 1.90%. Abbott Laboratories’s payout ratio is currently 87.60%.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/abbott-laboratories-abt-stake-boosted-by-toronto-dominion-bank/1802721.html.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.